![Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study - The Lancet Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study - The Lancet](https://www.thelancet.com/cms/attachment/3cc43973-9161-436d-bf55-be5a18c2f548/gr1.gif)
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study - The Lancet
![Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels | Nature Cell Biology Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels | Nature Cell Biology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41556-020-0532-x/MediaObjects/41556_2020_532_Fig1_HTML.png)
Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels | Nature Cell Biology
Follicular lymphoma-associated mutations in the V-ATPase chaperone VMA21 activate autophagy creating a targetable dependency
![Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study - The Lancet Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study - The Lancet](https://www.thelancet.com/cms/attachment/f8ef32d8-e2f9-4baf-b793-4a1ee10fea30/gr2_lrg.jpg)